Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of Anjianning (adalimumab) in pediatric plaque psoriasis
ChiCTR2100053012Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in plaque psoriasis, sponsored by First Hospital of China Medical University. Primary endpoint: PASI 75 response. Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2100053012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053012.